# Cardiol Therapeutics Inc (CRDL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CRDL
## Company Profile
- Ticker: CRDL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
- Tags: Immunology
## Stock Data
- Close: 2.22 USD
- Market cap: 132563075.99999999 USD
- Last updated: 2026-09-08
## Business Overview
Cardiol Therapeutics is a biotechnology company focused on inflammatory heart disease and cardiology-related immunology. Its story centers on whether anti-inflammatory approaches can improve cardiac outcomes in a focused setting.
## Why The Stock Is Moving

As of Sep 8, 2026, CRDL closed up 0.91% at $2.22. No new same-company headline was identified in the current news window.

## Geographic Base

Cardiol Therapeutics is headquartered in Canada and listed in the U.S. market. It sits in specialty cardiology biotechnology.

## Business Model

The company depends on clinical data, translational confidence, and the ability to keep a narrow cardiovascular pipeline moving. Investors watch efficacy, safety, and proof-of-concept work.

## Landscape Position

Cardiol occupies a specialized cardio-immunology niche within biotech. The stock is catalyst-sensitive because the market needs evidence that the platform can matter in cardiac disease.

## Future Catalysts

- CRDL is a small-cap biotech / diagnostics name with catalysts around product and pipeline updates, plus any strategic step that clarifies the company's direction. The market will care about whether there is still a viable growth path.

## Recent News
- 2021-05-06 13:11 EST — [Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering](https://biopharmsignal.com/news/CRDL/cardiol-announces-upsize-to-previously-announced-bought-deal-public-offering-084d2390) — Source: Cardiol Therapeutics Inc
- 2021-05-05 20:34 EST — [Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering](https://biopharmsignal.com/news/CRDL/cardiol-therapeutics-announces-15-million-bought-deal-public-offering-b757ddc0) — Source: Cardiol Therapeutics Inc